ISO 10555: Intravascular Catheter Standards for MDR and FDA

Introduction

ISO 10555 is the standard every intravascular catheter file cites and the one most of them cite wrongly. The series is the undisputed state of the art for sterile, single-use catheters, the FDA recognises its current editions, and every Notified Body reviewer expects to find its test reports in the file. Yet under the EU MDR not a single part of it carries a presumption of conformity, the general part was rewritten in 2023, and two of the particular parts are being revised as this is written. A test report that says "complies with ISO 10555" closes less than most manufacturers assume.

This guide is written for the engineer or regulatory lead who has to turn the series into evidence that survives review. It sits between the bench and the dossier: the test results are meaningless unless they are traceable to the hazards in your ISO 14971 risk management file and land in the right place in the EU MDR technical documentation, and most of the findings on catheter files are about that traceability rather than about the catheter.

We cover how the series is structured, its harmonisation and recognition status in 2026, what ISO 10555-1:2023 actually requires, how to choose the particular part, how to build the test plan from risk, how to map the evidence to the GSPR, what the FDA expects, the revisions in progress, and the six findings that recur.

Table of Contents

• How the ISO 10555 series is structured
• Part 1 is the backbone of every catheter test plan
• The particular parts add requirements, they do not replace Part 1
• Why ISO 10555 gives no presumption of conformity under the MDR
• What ISO 10555-1:2023 requires and what changed from 2013
• The core tests a Part 1 report must contain
• What the 2023 edition changed
• Choosing the particular part before you test anything
• A test plan built from risk, not from the standard's contents page
• Mapping ISO 10555 evidence to the GSPR and Annex II
• ISO 10555 in an FDA submission
• Parts 3 and 5 are being revised: what to do now
• Six findings that recur in catheter files
• Frequently asked questions
• Conclusions

How the ISO 10555 series is structured

The series is published by ISO/TC 84, the committee responsible for devices for the administration of medicinal products and catheters, and it follows a pattern familiar to anyone who has worked with IEC 60601: a general part that applies to every device in scope, and particular parts that add or modify requirements for one device family. The full title of every part begins with the same words, intravascular catheters, sterile and single-use catheters, and that title is the first scope filter. A catheter that is reusable, supplied non-sterile, or never enters the vascular system is outside the series entirely, whatever its shape.

Understanding the architecture matters because the most expensive mistake in catheter testing is structural, not technical. Teams commission a laboratory to "test to ISO 10555" without saying which parts, the laboratory quotes the general part, and the particular requirements that a reviewer will look for first are simply absent from the report.

Part 1 is the backbone of every catheter test plan

ISO 10555-1 specifies general requirements for intravascular catheters supplied sterile and intended for single use, for any application. It does not apply to catheter accessories such as guidewires, introducers and dilators, which are covered by ISO 11070. Its requirements cover the properties every catheter shares regardless of where its tip ends up: the surface must be free of extraneous matter and defects, the catheter must be detectable under imaging where that is claimed, metallic parts must resist corrosion, the size designation must follow a defined format, the tubing and every junction must withstand a minimum peak tensile force, the fluid path must not leak liquid under pressure or admit air during aspiration, the hub must be a compatible connector, the flowrate must be declared, and where the catheter is claimed to be suitable for power injection, that claim must be tested.

The previous Part 2, which covered angiographic catheters, no longer exists. Its content was folded into Part 1, which is why an angiographic, guiding or diagnostic catheter today is tested to Part 1 alone, supplemented by whatever additional tests the risk analysis and any device-specific guidance demand. That supplement is not optional, and it is where most of the engineering judgement in a catheter test plan lives.

The particular parts add requirements, they do not replace Part 1

Each particular part opens with a variant of the same sentence: the catheter shall comply with ISO 10555-1 unless otherwise specified in this document. That sentence defines the relationship. A central venous catheter is not tested to Part 3 instead of Part 1; it is tested to Part 1, with the exceptions and additions Part 3 lists. The current draft of the new Part 3, for example, replaces the Part 1 peak tensile force requirement of clause 4.9 with its own values for the relevant sections of the catheter while leaving every other Part 1 requirement in force.

Six particular parts are currently published or in revision. Part 3 covers central venous catheters, Part 4 balloon dilatation catheters, Part 5 over-needle peripheral catheters, Part 6 subcutaneous implanted ports, Part 7 peripherally inserted central catheters, and Part 8, the newest, catheters for extracorporeal blood treatment such as haemodialysis.

Around the series sits a ring of standards that every catheter file also cites. Biological evaluation follows ISO 10993-1, with ISO 10993-4 for interaction with blood. Ethylene oxide sterilisation follows ISO 11135 and the sterile barrier ISO 11607. Hubs are intravascular small-bore connectors under ISO 80369-7. Over-needle cannulae with a safety mechanism add ISO 23908. Knowing which of these are harmonised and which are not is the subject of the next section.

Why ISO 10555 gives no presumption of conformity under the MDR

Article 8 of the MDR is precise about what a harmonised standard buys you. Devices in conformity with harmonised standards, or the relevant parts of them, whose references have been published in the Official Journal are presumed to conform to the requirements of the Regulation those standards cover. The presumption attaches to the reference in the Official Journal, not to the quality or the reputation of the standard.

For the MDR, those references are collected in Implementing Decision (EU) 2021/1182, amended several times since, most recently by Decision (EU) 2026/1231 in June 2026. The list now includes the sterilisation standards a catheter manufacturer relies on, EN ISO 11135 and EN ISO 11137, the packaging standards EN ISO 11607-1 and -2, EN ISO 10993-1:2025 and EN ISO 10993-4 with its 2025 amendment, EN ISO 14971 and, since 2026, EN ISO 23908:2025 for sharps protection mechanisms on catheter introducers. It does not include any part of ISO 10555. Neither does it include ISO 80369-7, the connector standard every catheter hub is tested against. You can check the current state of the list on the European Commission harmonised standards page for medical devices.

The practical consequence is a change in the burden of proof, not in the testing. A catheter that passes every ISO 10555 test is no less safe because the standard is not listed. What changes is the argument the technical documentation has to make. With a harmonised standard, the GSPR checklist can cite the standard against the requirement and rely on the Annex ZA mapping the European version provides. Without it, the manufacturer has to demonstrate that each relevant clause addresses the specific GSPR it is cited against, and that the edition used represents the state of the art.

Writing "presumption of conformity" next to ISO 10555 in a GSPR checklist is a factual error a reviewer can verify in thirty seconds. Cite it as the generally acknowledged state of the art under Annex I, Chapter I, Section 1, and do the clause-to-requirement mapping yourself.

None of this makes ISO 10555 optional. A Notified Body will treat the current edition as the reference point for the state of the art, and departing from it requires a justification at least as strong as the evidence the standard would have produced. The absence of harmonisation removes a shortcut; it does not lower the bar.

What ISO 10555-1:2023 requires and what changed from 2013

ISO 10555-1:2023, the third edition, was published in November 2023 and cancelled and replaced the 2013 edition together with its 2017 amendment. The European adoption, EN ISO 10555-1:2023, reproduces the ISO text without changes. Any file that still cites ISO 10555-1:2013 without a documented assessment against the 2023 edition is carrying a finding waiting to be written.

The core tests a Part 1 report must contain

The normative requirements of Part 1 translate into a recognisable set of bench tests, most of them described in the standard's annexes. A complete Part 1 report addresses each of the following, or justifies in writing why a requirement does not apply to the design.

Sterility and biocompatibility appear in Part 1 as requirements to be met, but the evidence for them comes from the sterilisation validation and the biological evaluation, not from the ISO 10555 test laboratory. A Part 1 report that is silent on them is normal. A technical file that is silent on them is not.

What the 2023 edition changed

The 2023 revision clarified existing requirements and added new ones in clause 4, introduced a nominal inside diameter for some applications in clause 5, and required test details for power injection to appear in the instructions for use in clause 6. Annex G introduces an alternative power injection method using a constant flowrate source, which measures the pressure developed at a set flowrate rather than the flowrate achieved at a set pressure, and that is closer to how contrast injectors are actually programmed. The annexes on peak tensile force and air leakage were clarified, an under-water air leakage method was added, and informative guidance on distal tip stiffness was introduced, aimed mainly at neurovascular catheters. Packaging requirements now point to ISO 11607-1 and ISO 11607-2.

Not every change forces a retest. The sensible approach is a clause-by-clause gap assessment that classifies each 2013 test report as still valid, valid with a documented rationale, or superseded. Air leakage on a catheter tested by the aspiration method may well remain acceptable; a power injection claim whose IFU does not carry the test conditions does not, because the requirement is now about the information supplied as much as the bench result.

Choosing the particular part before you test anything

Particular-part selection is a design input decision, and it belongs in the design and development plan, not in the laboratory quotation. The order matters, because several families overlap. A haemodialysis catheter is a central catheter, but Part 8 was written for it. A PICC has its tip in the central veins, but Part 7 covers it, and the current draft of Part 3 states explicitly that PICCs are not part of its scope. Asking the questions in the right sequence avoids testing a device to a part a reviewer will not accept.

The decision tree also exposes the families that no particular part covers. Angiographic, guiding, diagnostic and micro-catheters, as well as many specialty infusion catheters, fall through every gate and land on Part 1 alone. For these devices the particular requirements a reviewer expects come from elsewhere: product-specific guidance, clinical practice, comparison with similar devices on the market, and above all the hazard analysis. Kink resistance, torque transmission, tip deflection and simulated use in a tortuous anatomical model are not ISO 10555-1 tests, but for a device that has to navigate the coronary or cerebral vasculature they are the tests that matter most.

Classification is a separate exercise and the series does not decide it. Under the MDR, catheters are classified under Rules 6, 7 and 8 of Annex VIII, according to duration of use and whether the device is in direct contact with the heart or the central circulatory system as Annex VIII defines it. Two catheters tested to the same ISO 10555 parts can end up in different classes, with different conformity assessment routes and different clinical evidence expectations.

A test plan built from risk, not from the standard's contents page

The single most useful shift in how a catheter file is built is to start from the hazard analysis and let ISO 10555 answer the question "how do we verify this risk control?" rather than "what does the standard want?". ISO 14971 requires risk control measures to be verified for implementation and effectiveness, and for a catheter most of the effectiveness evidence is bench testing. When the test plan is derived from the risk file, three things fall into place that a contents-page test plan misses.

First, the sample size has a rationale. ISO 10555 sets acceptance criteria but does not tell you how many devices to test. A reviewer will ask why ten catheters are enough to conclude that a tensile requirement protecting against fragment embolisation is met. The answer lives in the risk file: the severity of the harm drives the confidence and reliability levels, and those drive the number of samples. A tensile test on catheter separation, where the harm is embolisation of a fragment, deserves a higher reliability target than a cosmetic surface check.

Second, the samples are representative. Testing is performed on finished devices that have been through the full manufacturing process, including sterilisation at the worst-case condition, and where a shelf life is claimed, on aged devices as well as new ones. The worst-case sizes in a product family are identified and justified, not assumed. A family of central venous catheters in four diameters and three lengths does not need twelve full test campaigns, but it does need a documented argument for why the smallest diameter with the longest length represents the family for flowrate, and why the largest diameter represents it for something else.

Third, the gaps become visible. Where the hazard analysis identifies a risk that no ISO 10555 clause verifies, such as kinking under the clinical bend radius, coating particulate from a hydrophilic surface, or chemical compatibility with the drugs the catheter will carry, the test plan has to add a test. That is the point where a catheter file becomes specific to the catheter.

Biological evaluation follows the same logic. An intravascular catheter is in contact with circulating blood, and the biological endpoints and the contact duration have to be set according to the ISO 10993 series, including haemocompatibility under ISO 10993-4. A catheter that is replaced every few days in clinical practice but is labelled for up to thirty days of use is evaluated for thirty days. The evaluation uses the labelled duration, not the typical one.

Mapping ISO 10555 evidence to the GSPR and Annex II

Because the series is not harmonised, the GSPR checklist entry for a catheter cannot stop at the standard's number. Each relevant ISO 10555 requirement has to be mapped to the GSPR it supports, with the test report reference beside it. Done properly, this is not extra work; it is the same information the test plan already holds, organised the way an assessor reads a GSPR checklist.

In the technical documentation, the evidence lands in Annex II Section 6, product verification and validation, as test reports with a summary that states the standard and edition, the samples tested, the acceptance criteria, the results and the conclusion. Where a requirement was not tested, the summary says why. A list of reports without that summary forces the assessor to open every report to find the conclusion, and an assessor who has to do that will find the inconsistencies too.

Bench evidence also feeds two other documents. The clinical evaluation uses it to support the safety and performance claims that are not demonstrated clinically, and the benefit-risk analysis uses it to show that residual risks such as catheter fracture or air embolism are reduced as far as possible. When the three documents cite different test reports or different editions, the file contradicts itself.

ISO 10555 in an FDA submission

The FDA position is cleaner than the EU one, because recognition is explicit and editioned. ISO 10555-1:2023 is recognised under recognition number 6-499 and ISO 10555-4:2023 under 6-498. Recognition of the 2013 edition of Part 1, number 6-408, was superseded, and the FDA accepted declarations of conformity to it in premarket submissions only until 5 July 2026. A 510(k) submitted today that declares conformity to ISO 10555-1:2013 is declaring conformity to a standard the FDA no longer accepts for that purpose.

Two details catch European teams. Recognition can be partial, and the Supplementary Information Sheet for each standard in the FDA Recognized Consensus Standards database states which clauses are not recognised and what the FDA expects instead. And a declaration of conformity to a recognised standard means full conformity with the recognised parts: deviations have to be identified and justified, not left in a test report appendix.

Recognition also does not replace device-specific guidance. For peripheral PTA balloon catheters and specialty catheters such as infusion catheters and scoring or cutting balloons, the FDA final guidance of April 2023 on 510(k) submissions sets out non-clinical testing, animal and clinical study expectations and labelling that go well beyond ISO 10555-4. That guidance applies to catheters that are not combination products; a drug-coated balloon follows a different route entirely. The ISO report is the floor of an FDA testing package, not the package.

The FDA and the EU now point in the same direction on Part 1: the 2023 edition is the reference. A single gap assessment and retest campaign, designed once, closes both the FDA transition and the EU state-of-the-art question.

Parts 3 and 5 are being revised: what to do now

Two particular parts are moving. ISO 10555-3:2013 on central venous catheters is being replaced by a third edition that reached the draft international standard stage in 2026. The draft references ISO 10555-1:2023, states that PICCs are outside its scope and directs them to Part 7, and keeps its own peak tensile force values for parts of the catheter. ISO 10555-5:2013 is also being revised, under a new title that specifies over-needle peripheral intravenous catheters and narrows the scope to accessing the peripheral venous system; the draft ballot closed in May 2026.

A draft standard is not the state of the art, and testing to a DIS gives no regulatory advantage. What a manufacturer can do now is cheaper and more useful: read the drafts, identify the requirements that are likely to change, and make sure the design history file records the decision to test to the current editions with a commitment to reassess on publication. The periodic state-of-the-art review that already feeds the clinical evaluation update and the post-market surveillance reports is the natural place to log that commitment, so it is not left to someone's memory. When the new editions publish, the gap assessment is already scoped.

Part 8 deserves a separate mention. Published in August 2024 as a first edition, it gives haemodialysis and other extracorporeal blood treatment catheters a particular part for the first time, and an amendment is already in preparation. Dialysis catheter files written before 2024 tested to Part 1 and Part 3 by analogy; they now need a documented assessment against Part 8.

Six findings that recur in catheter files

The same six problems account for most ISO 10555-related questions on catheter technical documentation. None of them is about the catheter failing a test. All of them are about the evidence not saying what the manufacturer thinks it says.

The superseded edition is the commonest. Test reports from 2018 cite ISO 10555-1:2013, the file has never assessed them against the 2023 edition, and the GSPR checklist quietly updated the edition number without anyone checking the evidence underneath. The presumption-of-conformity claim follows close behind, usually copied from a template written for a harmonised standard. Unrepresentative samples, meaning prototypes, unsterilised devices or one size standing in for a family without a rationale, are the finding that costs most to close, because the only fix is to test again.

The wrong particular part is typically a PICC tested to Part 3, or a dialysis catheter never assessed against Part 8. An unsupported power injection claim is now easier for an assessor to spot, because the 2023 edition requires the test conditions in the IFU. An inconsistent size designation, where the label, the IFU, the test reports and the UDI device data express gauge, French size and millimetres differently, looks cosmetic but undermines the traceability of every report in the file.

Frequently asked questions

What is ISO 10555?

ISO 10555 is the international standard series for sterile, single-use intravascular catheters, published by ISO/TC 84. Part 1 sets general requirements for every catheter in scope, such as peak tensile force, leakage, hubs, flowrate and power injection. Particular parts add requirements for central venous catheters, balloon dilatation catheters, over-needle peripheral catheters, implanted ports, PICCs and catheters for extracorporeal blood treatment.

Is ISO 10555 harmonised under the EU MDR?

No. As of Implementing Decision (EU) 2026/1231, no part of ISO 10555 is listed among the harmonised standards for the MDR, so applying it gives no presumption of conformity. It remains the generally acknowledged state of the art, and manufacturers should map each relevant clause to the GSPR it supports instead of relying on a presumption.

What changed between ISO 10555-1:2013 and ISO 10555-1:2023?

The 2023 edition clarified and added requirements in clause 4, introduced a nominal inside diameter for some applications, required power injection test details in the instructions for use, added an alternative power injection method using a constant flowrate source, added an under-water air leakage method and guidance on distal tip stiffness, and referenced ISO 11607 for packaging. It also incorporated the 2017 amendment.

Does ISO 10555 apply to guidewires and introducers?

No. ISO 10555-1 does not apply to intravascular catheter accessories. Guidewires, introducers, dilators and similar accessories are covered by ISO 11070. Sharps protection mechanisms on introducers for catheters and needles are addressed by ISO 23908, whose 2025 edition is harmonised under the MDR.

Which part of ISO 10555 applies to PICC lines?

Peripherally inserted central catheters are covered by ISO 10555-7:2023 together with ISO 10555-1. They should not be tested to Part 3 as central venous catheters: the 2026 draft of the new Part 3 states explicitly that PICCs are outside its scope and refers to Part 7.

Is ISO 10555 recognised by the FDA?

Yes. ISO 10555-1:2023 is recognised under recognition number 6-499 and ISO 10555-4:2023 under 6-498. The FDA accepted declarations of conformity to the 2013 edition of Part 1 only until 5 July 2026. Check the Recognized Consensus Standards database for the extent of recognition of each part you cite.

Conclusions

ISO 10555 is the state of the art for intravascular catheters and nothing in this article argues for testing less. The argument is about what the testing proves. Under the MDR the series carries no presumption of conformity, so the file has to map its clauses to the GSPR and justify the edition. Under the FDA the 2023 edition of Part 1 is the only one accepted in new submissions. In both systems the particular part has to be chosen before the first sample is built, and the test plan has to come out of the hazard analysis rather than the standard's contents page.

If your catheter file still cites ISO 10555-1:2013, start with the gap assessment: it is a few days of work, it closes the FDA transition and the EU state-of-the-art question at once, and it tells you exactly which tests, if any, you need to repeat.

The Risk Management Documentation Kit on MD Regulatory includes the risk management plan, the ISO/TR 24971-based hazard analysis, design and use FMEAs and the GSPR checklist your ISO 10555 evidence has to trace through, and the EU MDR Technical Documentation Kit provides the Annex II structure the test reports belong in — both immediately deployable in an existing ISO 13485 quality management system.

Related articles

• Biocompatibility Testing for Medical Devices Under ISO 10993
• EU MDR Clinical Evaluation